ConTTRibute: Global Observational Multicenter Long-Term Study of Patients with Transthyretin (TTR)-Mediated Amyloidosis
Brief description of study
This is a prospective global multicenter long-term observational study designed to document the clinical outcomes of patients with hereditary transthyretin-mediated amyloidosis or wild-type transthyretin-mediated amyloidosis and the safety of patisiran (Onpattro) when used in patients with ATTRv amyloidosis.
This is data collection study only and no study medication no visits or procedures associated with the study. Patients will follow routine clinical care.
ATTR amyloidosis is a rare condition. The aim of this study is to learn as much as possible on this disease. Participation in the study is indefinite. Hence the study doctor will follow patients for as long as possible until patients withdraw or the sutdy is closed.
Because this is a non-interventional study no additional clinic visits and no additional tests or procedures are required as part of this study.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
-
Conditions:
amyloidosis
-
Age: Between 18 Years - 99 Years
-
Gender: All
Updated on
09 Mar 2024.
Study ID: 849352
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For cancer trials contact EmergingMed: 1-855-216-0098 or PennCancerTrials@emergingmend.com
